Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b open-label study of Sofosbuvir + ribavirin in HCV-infected subjects with renal insufficiency
2013-002897-30Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sofosbuvir in chronic hepatitis C (CHC) and hepatitis C virus infection (2 arms), sponsored by Gilead Sciences. Primary endpoint: Safety endpoints. Started Nov 2013; status: terminated.
02
Drugs
sofosbuvir
03
Conditions
chronic hepatitis C (CHC)hepatitis C virus infection
Beyond the preview
Go deeper on 2013-002897-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002897-30.